Adlyxin (lixisenatide), received FDA marketing approval.
In 2015, diabetes drugs cost England almost $1.3 billion, accounting for more than 10% of all PCP prescriptions. (BMJ)
Obesity and the flu? A study this week showed flu-vaccines weren't as effective in protecting obese mice. (mBio)
A study this week linked lack of exercise to Diabetic Retinopathy. (JAMA Ophthalmology)
New Senator Dianne Feinstein (D-Calif) is introducing a bill aimed at reducing the risk of exposure to endocrine-disrupting chemicals, linked to obesity, diabetes, and more. (Endocrine News)
A higher BMI does not necessarily mean a higher risk of heart attack or death, according to a Swedish twin study. (JAMA Internal Medicine)
Sanofi's Diabetes drug, Lantus, was dropped by CVS this week in favor of biosimilars. (Reuters)
Rise in T2D rates in Scotland attributed to an increase in longevity. (Diabetologia)
Capillary Biomedical announced this week support of research for development of a "new insulin infusion technology." (Business Wire)
"Obesity is just a high-income country problem": Forbes reported in an article listing the top seven misconceptions about the global obesity epidemic.
EndoBreak: Adlyxin Approved; Lantus Nixed by CVS
Aucun commentaire:
Enregistrer un commentaire